Low-cost anti-mycobacterial drug discovery using engineered E. coli

Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the pathogen’s slow growth and biocontainment requirements. Here we present a synthetic biology framework for assaying Mtb drug targets in engineered E. coli. We construct Target Essential Surrogate E. coli (TESEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bongaerts, Nadine, Edoo, Zainab, Abukar, Ayan A., Song, Xiaohu, Sosa-Carrillo, Sebastián, Haggenmueller, Sarah, Savigny, Juline, Gontier, Sophie, Lindner, Ariel B., Wintermute, Edwin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262897/
https://www.ncbi.nlm.nih.gov/pubmed/35798732
http://dx.doi.org/10.1038/s41467-022-31570-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262897/
https://www.ncbi.nlm.nih.gov/pubmed/35798732
http://dx.doi.org/10.1038/s41467-022-31570-3

Ejemplares similares